Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline
| Autor: | Hikaru Hori, Wakako Umene-Nakano, Reiji Yoshimura, Nobuhisa Ueda, Atsuko Ikenouchi-Sugita, Jun Nakamura |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Drug Resistance Refractory Sertraline Internal medicine Humans Medicine Pharmacology (medical) Psychiatry Depression (differential diagnoses) Aged Depressive Disorder Major Risperidone business.industry Brain-Derived Neurotrophic Factor Desmethylsertraline Drug Synergism Plasma levels Middle Aged medicine.disease Antidepressive Agents Psychiatry and Mental health Endocrinology Neurology Plasma concentration Major depressive disorder Drug Therapy Combination Female Neurology (clinical) business Antipsychotic Agents medicine.drug |
| Zdroj: | Human Psychopharmacology: Clinical and Experimental. 23:707-713 |
| ISSN: | 1099-1077 0885-6222 |
| DOI: | 10.1002/hup.979 |
| Popis: | In the present study, we examined the efficacy of risperidone addition on sertraline-resistant depressed patients and the effects of risperidone on the metabolism of sertraline. Ten patients (M/F: 4/6, age: 54 +/- 10 years) met the DSM-IV criteria for major depressive disorder enrolled the study. Hamilton Dating Scale for Depression (HAM-D) scores (mean +/- SD) in all 10 patients significantly decreased from 19 +/- 4 (before risperidone addition) to 11 +/- 3 (4 weeks after risperidone addition). Plasma levels of sertraline and desmethylsertraline did not change after risperidone addition. Serum BDNF levels in responders to risperidone addition were changed from 8.1 +/- 2.7 ng/ml (before risperidone addition) to 11.5 +/- 0.9 ng/ml (4 weeks after risperidone addition); in contrast, those in nonresponders changed from 7.8 +/- 2.2 ng/ml (before risperidone addition) to 7.9 +/- 2.4 ng/ml (4 weeks after risperidone addition). These results suggest that the addition of risperidone to sertraline is effective and well tolerated for sertraline-resistant depressive patients, which is accompanied with the increase in serum BDNF levels in responders to the risperidone addition, and the addition of risperidone to sertraline does not seem to influence sertraline metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|